Current problems and needs in the treatment of pT1 G3 bladder carcinoma.
Martínez Portillo
Francisco Jose
FJ
Department of Urology, University Hospital Mannheim, University of Heidelberg, Germany. fmartinez@urology.uni-kiel.de
Alken
Peter
P
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage*; D001707:Biopsy, Needle; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D015653:Cystectomy / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D020380:Needs Assessment; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*
D001500:BCG Vaccine